BioAtla, Inc. (BCAB) Social Stream
BIOATLA INC (BCAB) Price Targets From Analysts
Use the tables below to see what analysts covering BIOATLA INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-18 | 4 | $75 | $64 | $70.5 | $1.77 | 3883.05% |
| 2022-01-02 | 4 | $75 | $58 | $69 | $1.77 | 3798.31% |
| 2022-01-12 | 3 | $75 | $58 | $69 | $1.77 | 3798.31% |
| 2022-01-17 | 3 | $75 | $58 | $67.25 | $1.77 | 3699.44% |
| 2022-02-04 | 3 | $68 | $36 | $57.5 | $1.77 | 3148.59% |
| 2022-03-01 | 3 | $68 | $36 | $53.5 | $1.77 | 2922.6% |
| 2022-03-11 | 3 | $68 | $31 | $46.75 | $1.77 | 2541.24% |
| 2022-05-05 | 4 | $68 | $25 | $42.4 | $1.77 | 2295.48% |
| 2022-05-06 | 4 | $68 | $21 | $36.2 | $1.77 | 1945.2% |
| 2022-07-22 | 4 | $68 | $21 | $37.5 | $1.77 | 2018.64% |
| 2022-08-10 | 4 | $68 | $21 | $35.2 | $1.77 | 1888.7% |
| 2022-09-15 | 5 | $68 | $17 | $30.833 | $1.77 | 1641.98% |
| 2022-11-04 | 5 | $36 | $17 | $23.6 | $1.77 | 1233.33% |
| 2023-01-05 | 5 | $25 | $17 | $21.4 | $1.77 | 1109.04% |
| 2023-03-24 | 5 | $25 | $17 | $20.8 | $1.77 | 1075.14% |
| 2023-03-27 | 6 | $25 | $12 | $18.4 | $1.77 | 939.55% |
| 2023-03-28 | 6 | $25 | $12 | $17.5 | $1.77 | 888.7% |
| 2023-08-02 | 6 | $25 | $12 | $16.666 | $1.77 | 841.58% |
| 2023-09-25 | 6 | $25 | $12 | $15.833 | $1.77 | 794.52% |
| 2023-11-08 | 6 | $25 | $10 | $14.666 | $1.77 | 728.59% |
The Trend in the Analyst Price Target
Over the past 18 months, BCAB's average price target has gone down $27.6.
Over the past 44 weeks, BCAB's average upside potential has been 446.48%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-05 | 4 | 25 | 17 | 21.400 | 8.25 | 159.39% |
| 2023-04-03 | 6 | 25 | 12 | 16.833 | 2.83 | 494.81% |
| 2023-05-15 | 6 | 25 | 12 | 16.833 | 3.87 | 334.96% |
| 2023-09-25 | 6 | 25 | 12 | 15.833 | 1.72 | 820.52% |
| 2023-11-08 | 6 | 25 | 10 | 14.800 | 1.65 | 796.97% |
BCAB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
BCAB's average broker recommendation rating improved by 0.5 over the prior 29 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how BIOATLA INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 2732.66% of that group.
- BCAB has a greater number of analysts covering the stock than 515.37% of all US stocks.
- In the context of stocks in the mid market cap category, BIOATLA INC's variance in analysts' estimates is lower than -1877.86% of them.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, BIOATLA INC's average analyst price target is higher than 1230.02% of them.
Stocks similar to BIOATLA INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are SANA, TIL, and RXRX.
View All Top Stocks by Price Target
Make investment decisions regarding BCAB using the data that counts. Try POWR Ratings for free.